124 stories from 17 sources
The week in Medicine and Healthcare
Together, they made infectious-disease control the week's clearest pressure point.
Click on a headline to see stories that shaped it.
Threads
8 threads
Measles deaths in New York and Wisconsin gave the vaccination decline a fatal face before national case totals passed 5,000, the highest level in 35 years. The outbreak shifted pressure from isolated response to restoring broad immunization coverage.
The Ebola outbreak spread from Congo into Kenya and Uganda, prompting trials of vaccines for the responsible strain. A British patient's evacuation then brought the regional crisis into an international containment system.
Democrats moved from Senate control to control of both chambers, gaining leverage over confirmations, oversight, coverage, drug pricing, abortion, transgender care, and health AI. The shift reopened major policy fights, though it does not guarantee enactment.
CVS moved from considering a separation to planning a breakup of its retail pharmacy business from its insurance, pharmacy-benefit, specialty, and care operations. The reversal retreats from vertical integration as political scrutiny of healthcare giants intensifies.
Newly disclosed tumors in children treated with Zolgensma broadened into questions about cancer risks from the AAV vectors used across gene therapies. Developers and regulators now face pressure for deeper investigations and longer monitoring.
Federal Medicaid restrictions threatened coverage and hospital finances before states filed another lawsuit seeking to delay changes including work requirements. Implementation and the risk of coverage losses therefore remain unsettled.
Healthcare AI moved from rapid consumer and clinician adoption toward formal state rules for ambient systems and closer coordination with public agencies. Consent, privacy, accountability, and evidence of benefit emerged as the central deployment constraints.
A drug that sharply lowered lipoprotein(a) failed to reduce heart attacks or strokes, while a separate anti-inflammatory strategy also failed. The setbacks shifted cardiovascular research toward more precise targets and direct proof of clinical benefit.
Day’s Recap